2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,A...2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,ASH)会议中关于CAR-T细胞治疗血液恶性肿瘤的研究进展做一综述。展开更多
Objective： To investigate the expression of aquaporin 1 in cervical squamous carcinomas （CSC） and cervical precancerous lesions, and the relationship between the tumor clinicopathological parameters, prognosis and ...Objective： To investigate the expression of aquaporin 1 in cervical squamous carcinomas （CSC） and cervical precancerous lesions, and the relationship between the tumor clinicopathological parameters, prognosis and the expression of AQP1. Methods： Immunohistochemical method （EliVision） was used to detect the expression of AQP1 in samples from 106 patients [20 with normal cervical tissue, 30 with cervical intraepithelial neoplasia （stage Ⅰ and Ⅱ） and 56 with CSC]. Survival analysis was performed by Kaplan-Meier method. Results： AQP1 protein was expressed in vascular endothelia of all samples. It showed upregulation of AQP1 expression in CSC. There was a significant difference between CSC and normal cervical tissues （P〈0.05）. AQP1 was expressed in some tumor cells and unexpressed in normal squamous epithelial cells. And APQl-expressing tumor cells were positively related to lymph node metastasis. Patients with APQl-expressing tumor cells had the lower survival rate than the ones without. Conclusion： Abnormal expression of AQP1 plays an important role in the development of CSC. Positive expression of AQP1 in tumor cells maybe enhances tumor metastasis and could be used as a marker for tumor prognosis.展开更多
Objective： To investigate the antitumor activity of tumor lysate-pulsed dendritic cells vaccine in RM-1 prostate cancer mice model with the survival time of mice calculated and the tumor size measured in DC vaccine t...Objective： To investigate the antitumor activity of tumor lysate-pulsed dendritic cells vaccine in RM-1 prostate cancer mice model with the survival time of mice calculated and the tumor size measured in DC vaccine therapy. Methods： C57BL/6 mice were immunized on the dorsal flank by s.c. inoculation of Lysate-DC, ova-DC, and non-DC on day -7. On day 0, 2× 10^6cells of RM-1 tumor cells （H-2b） were injected s.c. in C57BL/6 mice pre-treated by s.c. inoculation of modified DCs, correspondingly. DTH assay was performed with modified DCs. In partial test, for the determination of which immune cells were required for antitumor activity, mice were immunodepleted of CD4, CDS, or natural killer （NK） NK1.1 cells with the corresponding monoclonal antibodies. The survival time of nude mice loaded with tumor cells was calculated and the size of tumor measured. Results： In RM-1 mice prostate cancer model, immunized with lysate-DC, compared with ova-DC and non-DC, the pre-infection vaccine resulted in 100% clearance of primary tumors, whereas on day 0 of injection vaccine cleared 40-60% of primary tumors. On day 0, C57BL/6 mice （H-2b） were immunized with Lysate-DC, compared with ova-DC and non-DC by caudal vein injection, then on day 15, RM-1 cells were inoculated. On day 30, average diameters of tumor in different groups of modified DC were 23.7±5.4 mm, 22.1±4.9 mm, 4.3±2.6 mm, respectively. Lysate-DC, compared with ova-DC and non-DC, can greatly depressed RM-1 tumor cell growth （P〈0.01）. The mean survival time of C57BL/6 mice in Lysate-DC, ova-DC and non-DC groups were 15.8±2.6, 16.6±3.2, 39.0±5.6, respectively, and there was a significant difference in the mean survival time in lysate-DC group between ova-DC and non-DC group （P〈0.01）. DTH test showed that lysate-DC could prime T lymphocyte and elicit tumor antigen specific immune response, and over 80% mice in groups of lysate-DC showed obvious swelling in their foot pad. This response was strengthened with repeating inoculation, whereas DTH response was not seen in control group. In vivo depletion of NK cells resulted in a 40-60% reduction in growth suppression within the primary tumor, and depletion of CD4^＋ cells resulted in a 20% reduction in growth suppression. Conclusion： The minor lysate-pulsed dendritic cells vaccine could elicit antitumor activity in RM-1 loaded C57BL/6 mice, and prolong the duration of RM-1 loaded C57BL/6 mice. So DC-based immunotherapy with hormone-refractory prostate carcinoma yielded protective immunity, generated efficient cellular antitumor responses, thereby providing further preclinical support for feasible immunotherapy approaches for prostate cancer.展开更多
Background： Thermothempy has already been proved effective for the treatment of various tumors, including glioma. This study was performed to determine whether tumor necrosis factor-alpha was involved in the regulati...Background： Thermothempy has already been proved effective for the treatment of various tumors, including glioma. This study was performed to determine whether tumor necrosis factor-alpha was involved in the regulation of this biological process. Methods： RT-PCR and immunocytochemistry were used to investigate the levels of tumor necrosis factor-alpha mRNA and heat shock factor-1 protein, respectively, in glioma cells. Radioimmunoassay was used to dynamically monitor contents of TNF-α in nutrient fluid for C6 cells after hyperthermia treatment. Crystal violet staining method was used to detect glioma invasiveness. Results： The most obvious increase of heat shock factor-1 protein and tumor necrosis factor -alpha mRNA in C6 cells were observed at 30 min and 60 min after hyperthermia, respectively. In addition, the radioactivity of tumor necrosis factor-alpha in C6 cells＇ culture fluid also reached peak at 120 min of hyperthermia. The glioma invasiveness decreases and the concentration of tumor necrosis factor-alpha reached the maximum at 120 min of hyperthermia. Conclusion： Our results showed that the hyperthermia-mediated glioma invasiveness decreases was due to accelerated release of tumor necrosis factor-alpha,which could cause the decreases of glioma invasiveness by promoting the release heat shock factor-1 from neurospongioma cells .展开更多
文摘2018年,随着诺贝尔生理学/医学奖的揭晓,检查点抑制剂治疗成为人类对抗癌症的里程碑,同时,嵌合抗原受体T细胞免疫治疗(chimeric antigen receptor T-cell immumotherapy,CAR-T)也是硕果累累的一年。本文将对过去一年来发表的血液肿瘤免疫治疗的相关文献以及第60届美国血液病学会(American Society of Hematology,ASH)会议中关于免疫治疗血液肿瘤研究进展作一综述。
文摘血液系统恶性肿瘤是最常见的癌症之一,目前,血液系统恶性肿瘤的主要治疗方法是干细胞移植、化疗和放疗,虽然有良好的治疗效果,但容易复发。嵌合抗原受体(chimeric antigen receptor,CAR)T细胞疗法作为一种革命性的细胞免疫治疗手段,为复发难治性(relapsed or refractory,R/R)血液恶性肿瘤患者带来了新的希望。
文摘2017年,在两款嵌合抗原受体T细胞免疫疗法(chimeric antigen receptor T-cell immumotherapy,CAR-T)细胞产品获批后,推进了全球细胞免疫治疗的研究。本文将对近一年来已发表的和第59届美国血液病学会(American Society of Hematology,ASH)会议中关于CAR-T细胞治疗血液恶性肿瘤的研究进展做一综述。
基金the Fund of Science and Technology Development Program of Shaanxi Province (2005K09-G6, 2005K09-G9)
文摘Objective： To investigate the expression of aquaporin 1 in cervical squamous carcinomas （CSC） and cervical precancerous lesions, and the relationship between the tumor clinicopathological parameters, prognosis and the expression of AQP1. Methods： Immunohistochemical method （EliVision） was used to detect the expression of AQP1 in samples from 106 patients [20 with normal cervical tissue, 30 with cervical intraepithelial neoplasia （stage Ⅰ and Ⅱ） and 56 with CSC]. Survival analysis was performed by Kaplan-Meier method. Results： AQP1 protein was expressed in vascular endothelia of all samples. It showed upregulation of AQP1 expression in CSC. There was a significant difference between CSC and normal cervical tissues （P〈0.05）. AQP1 was expressed in some tumor cells and unexpressed in normal squamous epithelial cells. And APQl-expressing tumor cells were positively related to lymph node metastasis. Patients with APQl-expressing tumor cells had the lower survival rate than the ones without. Conclusion： Abnormal expression of AQP1 plays an important role in the development of CSC. Positive expression of AQP1 in tumor cells maybe enhances tumor metastasis and could be used as a marker for tumor prognosis.
基金Supported by medical funds of Shanghai Science and Technology Commission
文摘Objective： To investigate the antitumor activity of tumor lysate-pulsed dendritic cells vaccine in RM-1 prostate cancer mice model with the survival time of mice calculated and the tumor size measured in DC vaccine therapy. Methods： C57BL/6 mice were immunized on the dorsal flank by s.c. inoculation of Lysate-DC, ova-DC, and non-DC on day -7. On day 0, 2× 10^6cells of RM-1 tumor cells （H-2b） were injected s.c. in C57BL/6 mice pre-treated by s.c. inoculation of modified DCs, correspondingly. DTH assay was performed with modified DCs. In partial test, for the determination of which immune cells were required for antitumor activity, mice were immunodepleted of CD4, CDS, or natural killer （NK） NK1.1 cells with the corresponding monoclonal antibodies. The survival time of nude mice loaded with tumor cells was calculated and the size of tumor measured. Results： In RM-1 mice prostate cancer model, immunized with lysate-DC, compared with ova-DC and non-DC, the pre-infection vaccine resulted in 100% clearance of primary tumors, whereas on day 0 of injection vaccine cleared 40-60% of primary tumors. On day 0, C57BL/6 mice （H-2b） were immunized with Lysate-DC, compared with ova-DC and non-DC by caudal vein injection, then on day 15, RM-1 cells were inoculated. On day 30, average diameters of tumor in different groups of modified DC were 23.7±5.4 mm, 22.1±4.9 mm, 4.3±2.6 mm, respectively. Lysate-DC, compared with ova-DC and non-DC, can greatly depressed RM-1 tumor cell growth （P〈0.01）. The mean survival time of C57BL/6 mice in Lysate-DC, ova-DC and non-DC groups were 15.8±2.6, 16.6±3.2, 39.0±5.6, respectively, and there was a significant difference in the mean survival time in lysate-DC group between ova-DC and non-DC group （P〈0.01）. DTH test showed that lysate-DC could prime T lymphocyte and elicit tumor antigen specific immune response, and over 80% mice in groups of lysate-DC showed obvious swelling in their foot pad. This response was strengthened with repeating inoculation, whereas DTH response was not seen in control group. In vivo depletion of NK cells resulted in a 40-60% reduction in growth suppression within the primary tumor, and depletion of CD4^＋ cells resulted in a 20% reduction in growth suppression. Conclusion： The minor lysate-pulsed dendritic cells vaccine could elicit antitumor activity in RM-1 loaded C57BL/6 mice, and prolong the duration of RM-1 loaded C57BL/6 mice. So DC-based immunotherapy with hormone-refractory prostate carcinoma yielded protective immunity, generated efficient cellular antitumor responses, thereby providing further preclinical support for feasible immunotherapy approaches for prostate cancer.
基金Supported by the Scientific Research Foundation of Hebei Provincial Department of Healththe Project of Science and Technology Research andDevelopment Plan of Tangshan City,Hebei Province(NO.20110165,20120144)(10140201A-15)
文摘Background： Thermothempy has already been proved effective for the treatment of various tumors, including glioma. This study was performed to determine whether tumor necrosis factor-alpha was involved in the regulation of this biological process. Methods： RT-PCR and immunocytochemistry were used to investigate the levels of tumor necrosis factor-alpha mRNA and heat shock factor-1 protein, respectively, in glioma cells. Radioimmunoassay was used to dynamically monitor contents of TNF-α in nutrient fluid for C6 cells after hyperthermia treatment. Crystal violet staining method was used to detect glioma invasiveness. Results： The most obvious increase of heat shock factor-1 protein and tumor necrosis factor -alpha mRNA in C6 cells were observed at 30 min and 60 min after hyperthermia, respectively. In addition, the radioactivity of tumor necrosis factor-alpha in C6 cells＇ culture fluid also reached peak at 120 min of hyperthermia. The glioma invasiveness decreases and the concentration of tumor necrosis factor-alpha reached the maximum at 120 min of hyperthermia. Conclusion： Our results showed that the hyperthermia-mediated glioma invasiveness decreases was due to accelerated release of tumor necrosis factor-alpha,which could cause the decreases of glioma invasiveness by promoting the release heat shock factor-1 from neurospongioma cells .
